The pathogenesis of endometrial carcinomas at menopause: Facts and figures

Journal of Clinical Pathology

Volumn 64, Issue 7, 2011, Pages 553-560

  Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADIPOSE TISSUE; ATROPHY; CANCER CLASSIFICATION; CANCER STAGING; CARCINOGENESIS; CELL TYPE; CLINICAL EVALUATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EVIDENCE BASED PRACTICE; FEMALE; GENETICS; HUMAN; MENOPAUSE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR CELL;

CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MENOPAUSE;

EID: 79959359948     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.085951     Document Type: Review

References (149)

1. AIHW. Australian Institute of Health and Welfare and the Australian Association of Cancer Registries. Cancer in Australia 1999. Canberra: AIHW and Australian Association of Cancer Registries, 2002.
2. Bray F, Dos Santos Silva I, Moller H, et al. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132-42. (Pubitemid 40656458)
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
4. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 2009;117:693-707.
5. Sivridis E, Fox H, Buckley C. Endometrial carcinoma: two or three entities? Int J Gynecol Cancer 1998;8:183-8.
6. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a gynecologic oncology group study. Cancer 2006;106:812-19. (Pubitemid 43238448)
7. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008;34:776-83.
8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17. (Pubitemid 13194678)
9. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5. (Pubitemid 15230596)
10. Deligdisch L, Holinka CF. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986;57:1385-8. (Pubitemid 16136760)
11. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308. (Pubitemid 30207514)
12. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982;49:1511-23.
13. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999;74:385-94. (Pubitemid 29439878)
14. Trope C, Kristensen GB, Abeler VM. Clear-cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynaecol 2001;15:433-46. (Pubitemid 32631475)
15. Sivridis E. An Immunohistochemical Study of Endometrial Hyperplasia and Neoplasia. PhD thesis. UK: University of Manchester, 1986.
16. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978;38:4360-6. (Pubitemid 9054232)
17. Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol 1976;19:775-88. (Pubitemid 8007370)
18. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985;60:174-7. (Pubitemid 15194667)
19. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 1998;19:593-607. (Pubitemid 28467713)
20. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45 (1 Suppl):277-82.
21. Nagamani M, Hannigan EV, Dillard EA Jr, et al. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1986;62:508-12. (Pubitemid 16138168)
22. Mollerstrom G, Carlstrom K, Lagrelius A, et al. Is there an altered steroid profile in patients with endometrial carcinoma? Cancer 1993;72:173-81.
23. Knab DR. Estrogen and endometrial carcinoma. Obstet Gynecol Surv 1977;32:267-81. (Pubitemid 8111003)
24. Tseng L, Mazella J, Funt MI, et al. Preliminary studies of aromatase in human neoplastic endometrium. Obstet Gynecol 1984;63:150-4. (Pubitemid 14177244)
25. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966;19:489-520.
26. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476-9.
27. Southcott BM. Carcinoma of the endometrium. Drugs 2001;61:1395-405. (Pubitemid 32783743)
28. Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006;101:470-5. (Pubitemid 43729980)
29. Burbos N, Musonda P, Giarenis I, et al. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer 2010;102:1201-6.
30. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-97. (Pubitemid 351880837)
31. Kirschner MA, Schneider G, Ertel NH, et al. Obesity, androgens, estrogens, and cancer risk. Cancer Res 1982;42(8 Suppl):3281-5.
32. Pettersson B, Bergstrom R, Johansson ED. Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol 1986;25:223-33.
33. Azziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 1989;52:703-25. (Pubitemid 19276720)
34. Nyholm HC, Nielsen AL, Lyndrup J, et al. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993;100:1115-19. (Pubitemid 24003622)
35. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-81. (Pubitemid 32385843)
36. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-32. (Pubitemid 37549609)
37. Chang RJ, Judd HL. The ovary after menopause. Clin Obstet Gynecol 1981;24:181-91. (Pubitemid 11104972)
38. Potischman N, Hoover RN, Brinton LA, et al. Case - control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35. (Pubitemid 26274607)
39. Aiman J. Age, estrogen, and the endometrium. Clin Obstet Gynecol 1981;24:193-202. (Pubitemid 11104973)
40. Tseng L, Mazella J, Mann WJ, et al. Estrogen synthesis in normal and malignant human endometrium. J Clin Endocrinol Metab 1982;55:1029-31. (Pubitemid 13054375)
41. Jongen VH, Hollema H, Van Der Zee AG, et al. Aromatase in the context of breast and endometrial cancer. A review. Minerva Endocrinol 2006;31:47-60.
42. Fox H, Sen DK. A controlled study of the constitutional stigmata of endometrial adenocarcinoma. Br J Cancer 1970;24:30-6.
43. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990;11:443-53. (Pubitemid 20261695)
44. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9. (Pubitemid 26277956)
45. Weiss NS, Hill DA. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 1996;23:235-9. (Pubitemid 26160448)
46. Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42. (Pubitemid 32175106)
47. Lundberg V, Tolonen H, Stegmayr B, et al. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004;48:39-49. (Pubitemid 38829105)
48. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
49. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-7.
50. MacDonald PC, Edman CD, Hemsell DL, et al. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978;130:448-55. (Pubitemid 8291952)
51. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case - control study. N Engl J Med 1979;300:9-13. (Pubitemid 9095976)
52. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
53. Beresford SA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61. (Pubitemid 27077825)
54. Weiderpass E, Adami HO, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84. (Pubitemid 29358961)
55. Beral V, Reeves G, Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 2005;112:692-5. (Pubitemid 40852833)
56. Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
57. Robertson WB. The Endometrium. London: Butterworths, 1981.
58. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30. (Pubitemid 32049639)
59. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-43. (Pubitemid 36020003)
60. Polednak AP. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev 2003;27:415-21. (Pubitemid 37506954)
61. Bray F, Loos AH, Oostindier M, et al. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer 2005;117:123-31. (Pubitemid 41262766)
62. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
63. Lepine J, Audet-Walsh E, Gregoire J, et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 2010;95:2689-98.
64. Niwa K, Murase T, Furui T, et al. Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice. Jpn J Cancer Res 1993;84:951-5. (Pubitemid 23280229)
65. Sivridis E, Giatromanolaki A. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. J Clin Pathol 2004;57:840-4. (Pubitemid 39061433)
66. Archer DF, McIntyre-Seltman K, Wilborn WW Jr, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 1991;165:317-20; discussion 20-2.
67. Korhonen MO, Symons JP, Hyde BM, et al. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997;176:377-80. (Pubitemid 27107926)
68. Rance NE. Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. Peptides 2009;30:111-22.
69. Zaino RJ. Interpretation of Endometrial Biopsies and Curettings. Philadelphia: Lippincott-Raven, 1996.
70. Speroff L, Glass R, Kase N. Clinical Gynecological Endocrinology and Infertility. 5th edn. Baltimore: Williams and Wilikins, 1994.
71. Reyes FI, Winter JS, Faiman C. Pituitaryeovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 1977;129:557-64.
72. Overlie I, Morkrid L, Andersson AM, et al. Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition. Acta Obstet Gynecol Scand 2005;84:281-5. (Pubitemid 40333109)
73. Buckley CH, Fox H. Biopsy Pathology of the Endometrium. 2nd edn. London: Arnold, 2002.
74. Snijders MP, de Goeij AF, Debets-Te Baerts MJ, et al. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 1992;94:363-71.
75. Noci I, Borri P, Scarselli G, et al. Morphological and functional aspects of the endometrium of asymptomatic post-menopausal women: does the endometrium really age? Hum Reprod 1996;11:2246-50.
76. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985;56:403-12.
77. Mutter GL, Zaino RJ, Baak JP, et al. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26:103-14. (Pubitemid 46573204)
78. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19:417-32.
79. Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004;12:207-23. (Pubitemid 39063348)
80. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch 2001;439:118-26. (Pubitemid 32758904)
81. Sivridis E, Giatromanolaki A, Liberis V, et al. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' 'structures (SLS). What is destined for the atypical endometrial hyperplasia? Autophagy 2011;7:74-82.
82. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol 2009;2:411-32.
83. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95:593-6. (Pubitemid 39610410)
84. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004;11:117-42.
85. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-6. (Pubitemid 43361894)
86. Faratian D, Stillie A, Busby-Earle RM, et al. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 2006;16:972-8. (Pubitemid 43886712)
87. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16:46-52.
88. Mazur MT, Kurman RJ. Diagnosis of Endometrial Biopsies and Curettings. A Practical Approach. New York: Springer, 1995.
89. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093-103.
90. Kuwabara Y, Susumu N, Banno K, et al. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. Jpn J Clin Oncol 2005;35:23-7.
91. Matthews RP, Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:206-12. (Pubitemid 27216929)
92. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol 1982;77:534-40. (Pubitemid 12112396)
93. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
94. Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol 1995;59:384-9.
95. Malpica A, Tornos C, Burke TW, et al. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995;19:769-74.
96. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-9. (Pubitemid 38388137)
97. Sagr ER, Denschlag D, Kerim-Dikeni A, et al. Prognostic factors and treatmentrelated outcome in patients with uterine papillary serous carcinoma. Anticancer Res 2007;27:1213-17. (Pubitemid 46587043)
98. Benito V, Lubrano A, Arencibia O, et al. Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 2009;19:1364-9.
99. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55:1272-6. (Pubitemid 36338293)
100. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996;78:1740-7.
101. Abeler VM, Kjorstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 1991;68:98-105.
102. Altrabulsi B, Malpica A, Deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005;29:1316-21. (Pubitemid 41368767)
103. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 highgrade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007;31:979-87. (Pubitemid 47012293)
104. Sivridis E, Giatromanolaki A. Endometrial adenocarcinoma: beliefs and scepticism. Int J Surg Pathol 2004;12:99-105. (Pubitemid 38542481)
105. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 2010;63:410-15.
106. Sivridis E, Giatromanolaki A. Endometrial adenocarcinoma: an apostasy from early views. Gynecol Oncol 2004;95:772-3. (Pubitemid 39592559)
107. Zaino RJ. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 2009;28:1-9.
108. Gemer O, Uriev L, Voldarsky M, et al. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. Eur J Surg Oncol 2009;35:247-51.
109. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304. (Pubitemid 40321964)
110. Scholten AN, Smit VT, Beerman H, et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004;100:764-72. (Pubitemid 38176855)
111. Lax SF, Kurman RJ, Pizer ES, et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000;24:1201-8.
112. Taylor RR, Zeller J, Lieberman RW, et al. An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol 1999;74:3-6. (Pubitemid 29331160)
113. Melhem MF, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinicopathological review of 18 cases. Int J Gynecol Pathol 1987;6:347-55.
114. Lax SF, Pizer ES, Ronnett BM, et al. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 1998;29:924-31. (Pubitemid 28422040)
115. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-23. (Pubitemid 38446432)
116. Ross JC, Eifel PJ, Cox RS, et al. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 1983;7:715-29. (Pubitemid 14222460)
117. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40. (Pubitemid 27427679)
118. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10. (Pubitemid 29001474)
119. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-17. (Pubitemid 30161349)
120. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
121. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-8.
122. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
123. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-9. (Pubitemid 32118131)
124. Tashiro H, Lax SF, Gaudin PB, et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997;150:75-9. (Pubitemid 27027098)
125. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-4. (Pubitemid 28467540)
126. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res 2000;6:2999-3005. (Pubitemid 30637721)
127. Maxwell GL, Risinger JI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-22. (Pubitemid 32184704)
128. Rosenberg P, Wingren S, Simonsen E, et al. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol 1989;35:50-4. (Pubitemid 19257745)
129. Prat J, Oliva E, Lerma E, et al. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994;74:1778-83.
130. Pradhan M, Abeler VM, Danielsen HE, et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 2006;19:1227-35. (Pubitemid 44268193)
131. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
132. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85. (Pubitemid 27027108)
133. Kovalev S, Marchenko ND, Gugliotta BG, et al. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998;29:613-19. (Pubitemid 28272717)
134. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122-6. (Pubitemid 32963063)
135. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008;14:2263-9. (Pubitemid 351551056)
136. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39:46-54.
137. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
138. Pere H, Tapper J, Wahlstrom T, et al. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res 1998;58:892-5. (Pubitemid 28182453)
139. Risinger JI, Berchuck A, Kohler MF, et al. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7:98-102. (Pubitemid 24232388)
140. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.
141. Singh M, Spoelstra NS, Jean A, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 2008;21:912-23. (Pubitemid 351896667)
142. Holcomb K, Delatorre R, Pedemonte B, et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002;100:1290-5. (Pubitemid 35449197)
143. Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004;10:5546-53. (Pubitemid 39100494)
144. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-52. (Pubitemid 41079838)
145. Announcements. FIGO stages - 1988 revision. Gynecol Oncol 1989;35:125-7.
146. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-6.
147. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/betacatenin pathway in endometrial cancer. Oncogene 2002;21:7981-90. (Pubitemid 35430609)
148. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-8. (Pubitemid 28376543)
149. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-12. (Pubitemid 34298736)